- BioAtla (BCAB), a biopharma developing antibody-based therapeutics for cancer, has priced its IPO of 10.5M shares of common stock at $18.00/share, for expected gross proceeds of ~$189M.
- The company initially planned to offer 9.4M shares at a range of $15-$17.
- Underwriters' over-allotment is an additional 1.575M shares.
- Trading kicks off December 16. Closing date is December 18.
- https://seekingalpha.com/news/3644744-bioatla-prices-ipo-above-range-18
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.